New drug cocktail shows promise in battling bone marrow cancer

NCT ID NCT04822337

Ongoing Disease control Sponsor: Wake Forest University Health Sciences Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 14, 2026 · Updated 3 times

Summary

This study is testing a new drug called belantamab mafodotin when added to three standard chemotherapy drugs (carfilzomib, lenalidomide, and dexamethasone) for people with multiple myeloma, a type of blood cancer. The goal is to find the safest dose and see if this combination can improve how well the cancer responds. About 70 participants will be enrolled in this early-phase trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: belantamab mafodotin, carfilzomib, lenalidomide, dexamethasone
What this could lead to: If successful, this combination could offer a more effective treatment option for multiple myeloma, potentially leading to better disease control.
What could go wrong: This is an early-phase trial with a small number of participants. The combination may cause significant side effects, and it is not yet known if it will be better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma plasma cell neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Winston-Salem, North Carolina, 27157, United States
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.